EN | UA
EN | UA

Help Support

Back

Canakinumab improves joint tenderness, swelling and reduces pain relief in patients experiencing a gout flare

Canakinumab improves joint tenderness, swelling and reduces pain relief in patients experiencing a gout flare Canakinumab improves joint tenderness, swelling and reduces pain relief in patients experiencing a gout flare
Canakinumab improves joint tenderness, swelling and reduces pain relief in patients experiencing a gout flare Canakinumab improves joint tenderness, swelling and reduces pain relief in patients experiencing a gout flare

What's new?

Canakinumab found to be superior to other anti-inflammatory therapies on day 2.

Canakinumab was found to be superior to other anti-inflammatories and intravenous (IV) or intramuscular (IM) corticosteroids may be the following best option for pain relief in patients suffering from gout flare. Swelling of the joint and patient global assessment can be improved with the help of acetic acid derivative NSAIDs, as concluded from a systematic review and network metaanalysis in ‘Arthritis Care and Research’.

The effectiveness of pharmacological antiinflammatory therapies for gout flares has been explored in this study.

The databases- Ovid Medline, Embase and Cochrane library were searched for randomized controlled trials (RCTs) concerning pharmacological antiinflammatory therapies of gout flares. The frequentist framework was used to conduct the network metaanalysis (NMA). Later, GRADE was used to assess the surety of evidence and create deductions.

Canakinumab provided the highest pain reduction at day 2 and at longest followup in the 30 eligible RCTs. IV or IM corticosteroids was inferior as compared to canakinumab but may be better than other frequently used therapies (low to very low certainty). At day 2, canakinumab may be the most effective therapy concerning joint tenderness. Also, acetic acid derivative NSAIDs improved joint swelling better than profen NSAIDs (Mean difference [MD] 0.29 on a 0 to 4 scale; moderate certainty) and improved patient global assessment (PGA) better than profen NSAIDs at the lengthiest followup (MD 0.44; moderate).

Source:

Arthritis Care and Research

Article:

Comparative efficacy and safety of pharmacological interventions in patients experiencing a gout flare: a systematic review and network meta‐analysis

Authors:

Linan Zeng et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: